SEC Form 4 · accession 0001209191-15-051829
CONCERT PHARMACEUTICALS, INC. · CNCE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Silverman
Officer — Senior VP, General Counsel
Period of report
Jun 8, 2015
Accepted (ET)
Jun 10, 2015 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001367920
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 8, 2015 | S | 5,000 | $16.3516 | D | 15,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2014.
- F2Represents the weighted average sales price for shares sold in mutltiple transactions. Sales prices ranged from $16.00 to $16.90 per share. Upon request of the staff of the Securities and Exchance Commission, the issuer or a security holder of the issuer, the reporting person will provide full information regarding the number of shares sold at each separate price.